Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 4/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340644 | 1.00 | MCHR1 (0.39) | MCHR1CA12CA2CA9FAAH | |
| SCHEMBL31424961 | 0.95 | MCHR1 (0.39) | MCHR1CA12CA2CA9FAAH | |
| SCHEMBL30544640 | 0.92 | MCHR1 (0.34) | MCHR1CA12CA2CA9FAAH | |
| SCHEMBL10773783 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C | |
| SCHEMBL3086955 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C | |
| SCHEMBL31648088 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C | |
| SCHEMBL2374757 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C | |
| SCHEMBL15272323 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C | |
| SCHEMBL5902719 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C | |
| SCHEMBL25613650 | 0.87 | MCHR1 (0.47) | MCHR1CA12CA2CA9PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332112-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4574172-A2 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-06-25 | — | — | EP | disclosed |
| EP-4466250-B1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025052278-A1 | PYRROLIDINE BASED CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2025-03-13 | — | — | WO | disclosed |
| EP-4466250-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023144798-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332112-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | CETP, NPC1L1, ABCB4 | MCHR1 2337/4885CA12 944/4885CA2 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.